Charles Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.

Researchers have clarified the process by which developing nerve cells are directed to specialize into distinct parts.

Researchers have shed light on how an important treatment for early-stage bladder cancer enters cancer cells to eradicate them.

The American Society of Clinical Oncology’s notable research advances include the approval of a new drug for men with advanced prostate cancer that was developed and studied by Memorial Sloan-Kettering researchers.

Our Office of Diversity Programs offers information and resources about clinical care, research, and training focused on reducing cancer health disparities in medically underserved populations.

Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs.

Recent findings by Memorial Sloan-Kettering immunologists might one day pave the way for new strategies to control a range of diseases, including autoimmune disorders and cancer.